Ideas

December 28, 2018

Molecular regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Ramipril (brand names: Altace, Prilace Novapril, Ramitens, Ampril, Corpril, Piramil, Prilinda and others), a drug used to treat hypertension, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, 28/December/2018, 9.36 pm

Molecular regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Ramipril (brand names: Altace, Prilace Novapril, Ramitens, Ampril, Corpril, Piramil, Prilinda and others), a drug used to treat hypertension, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, 28/December/2018, 9.36 pm https://genomediscovery.org/wp-content/uploads/2018/12/Ramipril-increases-the-expression-of-CAV1-and-GLP1R-augments-insulin-secretion-and-sensitivity-promotes-glucose-tolerance.jpg2_.jpg3_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/Ramipril-increases-the-expression-of-CAV1-and-GLP1R-augments-insulin-secretion-and-sensitivity-promotes-glucose-tolerance.jpg2_.jpg3_.jpg December 28, 2018 December 29, 2018

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April…

December 26, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing lncRNA Hand2-AS1 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such a SMAD7/CDK2AP1, BIRC5, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 26/December/2018, 7.55 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing lncRNA Hand2-AS1 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such a SMAD7/CDK2AP1, BIRC5, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 26/December/2018, 7.55 pm https://genomediscovery.org/wp-content/uploads/2018/12/LncRNA-Hand2-AS1-and-the-probiotic-Lactobacillus-attenuate-metastatic-cancer-progression-through-induction-of-SMAD7-and-BIRC5.jpg3_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/LncRNA-Hand2-AS1-and-the-probiotic-Lactobacillus-attenuate-metastatic-cancer-progression-through-induction-of-SMAD7-and-BIRC5.jpg3_.jpg December 26, 2018 December 26, 2018

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in…

December 26, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Pimozide, an antipsychotic drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as CADM2, FOXO1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 26/December/2018, 7.46 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Pimozide, an antipsychotic drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as CADM2, FOXO1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 26/December/2018, 7.46 pm https://genomediscovery.org/wp-content/uploads/2018/12/Pimozide-and-the-probiotic-Lactobacillus-fns-as-an-antitumor-agent-through-induction-of-FOXO1-and-CADM2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/Pimozide-and-the-probiotic-Lactobacillus-fns-as-an-antitumor-agent-through-induction-of-FOXO1-and-CADM2.jpg December 26, 2018 December 26, 2018

December 26, 2018

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, BIRC5, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 26/December/2018, `7.32 pm

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, BIRC5, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 26/December/2018, `7.32 pm https://genomediscovery.org/wp-content/uploads/2018/12/Probiotic-Clostridium-butyricum-MIYAIRI-588-CBM588-functions-as-an-antimetastasis-agent-through-induciton-of-BIRC5-and-PDCD4.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/Probiotic-Clostridium-butyricum-MIYAIRI-588-CBM588-functions-as-an-antimetastasis-agent-through-induciton-of-BIRC5-and-PDCD4.jpg December 26, 2018 December 26, 2018

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors…

December 26, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing MiRNA-129 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BTG2, RECK, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 26/December/2018, `7.10 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing MiRNA-129 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BTG2, RECK, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 26/December/2018, `7.10 pm https://genomediscovery.org/wp-content/uploads/2018/12/MiR129-and-the-probiotic-Lactobacillus-fn-as-an-antitumor-agent-through-induction-of-BTG2-and-RECK1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/MiR129-and-the-probiotic-Lactobacillus-fn-as-an-antitumor-agent-through-induction-of-BTG2-and-RECK1.jpg December 26, 2018 December 26, 2018

December 26, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing SAHA (Suberoylanilide Hydroxamic Acid) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as APAF1 and PIAS3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 26/December/2018, `6.31 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing SAHA (Suberoylanilide Hydroxamic Acid) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as APAF1 and PIAS3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 26/December/2018, `6.31 pm https://genomediscovery.org/wp-content/uploads/2018/12/SAHA-and-the-probiotic-Lactobacillus-fn-as-antitumor-agents-through-induction-of-PIAS3-and-APAF1.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/SAHA-and-the-probiotic-Lactobacillus-fn-as-antitumor-agents-through-induction-of-PIAS3-and-APAF1.jpg2_.jpg December 26, 2018 December 26, 2018

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in…

Popular Post